Physician profile
Nisreen Ezzi
NPI 1912231010
$9,403.18
in general payments reported to CMS, 2019-2025
30 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $992 · 2021: $1,428 · 2022: $1,492 · 2023: $1,194 · 2024: $2,173 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,883.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,731.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,021.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $939.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $674.81 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $595.77 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $581.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.29 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $558.39 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $553.60 | 2021-2025 | Ztlido |
| Merck Sharp & Dohme LLC | $259.07 | 2019-2021 | |
| Pfizer INC. | $244.61 | 2021-2025 | |
| Shield Therapeutics INC | $242.25 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $240.14 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $153.51 | 2019-2024 | |
| Dexcom, INC. | $143.71 | 2022-2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $101.84 | 2023-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $88.16 | 2023-2025 | Afrezza |
| Renalytix Ai, INC. | $83.73 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $79.05 | 2022-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.29 | 2024-2025 | Caplyta |
| Abbott Laboratories | $70.19 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amphastar Pharmaceuticals, INC. | $65.10 | 2024-2025 | |
| Dermavant Sciences, INC. | $65.08 | 2023-2024 | Vtama |
| Bayer Healthcare Pharmaceuticals INC. | $61.52 | 2022-2024 | |
| Evoke Pharma, INC. | $54.80 | 2021-2024 | |
| Genentech USA, INC. | $42.72 | 2020-2022 | |
| Cipher Pharmaceuticals US LLC | $42.15 | 2025 | Natroba, Spinosad |
| Lundbeck LLC | $33.80 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $21.74 | 2025 | Symbravo |
| Bausch Health US, LLC | $16.28 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisreen Ezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.